BBIO

66.39

2.04% 1.33

Dopo l'orario di chiusura: 66.60 0.21 +0.32%

Bridgebio Pharma Inc (BBIO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BBIO Giù? Forum Previsione

Precedente Chiudi:

$65.06

Aprire:

$64

Volume 24 ore:

1.54M

Relative Volume:

0.66

Capitalizzazione di mercato:

$12.69B

Reddito:

$217.77M

Utile/perdita netta:

$-438.86M

Rapporto P/E:

-27.55

EPS:

-2.41

Flusso di cassa netto:

$-456.33M

1 W Prestazione:

+7.43%

1M Prestazione:

+17.50%

6M Prestazione:

+97.24%

1 anno Prestazione:

+175.36%

Intervallo 1D:

$63.91

$67.71

Intervallo di 1 settimana:

$62.06

$67.93

Portata 52W:

$21.72

$69.48

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Nome

Bridgebio Pharma Inc

Settore

Healthcare (1135)

Industria

Biotechnology (634)

Telefono

(650) 391-9740

Indirizzo

3160 PORTER DR., PALO ALTO, CA

Dipendente

730

Cinguettio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

BBIO's Discussions on Twitter

Confronta BBIO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BBIO Bridgebio Pharma Inc	66.39	12.54B	217.77M	-438.86M	-456.33M	-2.41
VRTX Vertex Pharmaceuticals Inc	437.15	110.25B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	693.50	73.04B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	449.16	59.98B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	907.98	54.90B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	193.22	40.73B	447.02M	-1.18B	-906.14M	-6.1812

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-30	Ripresa	Raymond James	Outperform
2025-07-21	Iniziato	Truist	Buy
2025-07-14	Iniziato	Jefferies	Buy
2025-07-09	Aggiornamento	Oppenheimer	Perform → Outperform
2025-06-17	Iniziato	Wolfe Research	Outperform
2025-03-31	Iniziato	Redburn Atlantic	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-10-03	Iniziato	Oppenheimer	Perform
2024-09-04	Iniziato	Piper Sandler	Overweight
2024-03-21	Ripresa	Raymond James	Outperform
2024-01-31	Iniziato	BMO Capital Markets	Market Perform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-11-07	Iniziato	Citigroup	Buy
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-07-18	Downgrade	Jefferies	Buy → Hold
2023-04-19	Iniziato	Evercore ISI	Outperform
2023-02-06	Iniziato	Cowen	Outperform
2021-12-27	Reiterato	Mizuho	Buy
2021-12-27	Reiterato	SVB Leerink	Outperform
2021-09-10	Aggiornamento	BofA Securities	Neutral → Buy
2021-05-21	Iniziato	UBS	Buy
2021-03-22	Reiterato	Goldman	Buy
2021-02-22	Ripresa	JP Morgan	Overweight
2021-02-09	Ripresa	Goldman	Buy
2021-01-11	Reiterato	H.C. Wainwright	Buy
2020-12-10	Reiterato	H.C. Wainwright	Buy
2020-06-25	Iniziato	BofA/Merrill	Neutral
2020-05-19	Iniziato	BTIG Research	Buy
2020-04-13	Iniziato	H.C. Wainwright	Buy
2020-02-19	Iniziato	Mizuho	Buy
2019-07-26	Iniziato	Raymond James	Outperform
2019-07-22	Iniziato	BMO Capital Markets	Outperform
2019-07-22	Iniziato	Goldman	Buy
2019-07-22	Iniziato	JP Morgan	Overweight
2019-07-22	Iniziato	Jefferies	Buy
2019-07-22	Iniziato	Piper Jaffray	Overweight
2019-07-22	Iniziato	SVB Leerink	Outperform

Mostra tutto

Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie

Nov 15, 2025

(BBIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Nov 15, 2025

What moving averages say about BridgeBio Pharma Inc.Market Growth Report & Fast Gain Stock Tips - newser.com

Nov 15, 2025

How dovish Fed policy supports BridgeBio Pharma Inc. (2CL) stock2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com

Nov 15, 2025

Why BridgeBio Pharma Inc. (2CL) stock stays resilientWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com

Nov 15, 2025

Nov 13, 2025

What drives BridgeBio Pharma Inc stock priceDividend Aristocrats List & Fast Growing Portfolio Trading - earlytimes.in

Nov 13, 2025

Nov 12, 2025

What indicators show strength in BridgeBio Pharma Inc.2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com

Nov 12, 2025

How BridgeBio Pharma Inc. stock performs in stagflationWeekly Risk Report & Consistent Income Trade Recommendations - newser.com

Nov 12, 2025

Analysts Conflicted on These Healthcare Names: Incyte (INCY), Wave Life Sciences (WVE) and BridgeBio Pharma (BBIO) - The Globe and Mail

Nov 12, 2025

BridgeBio Pharma (BBIO): Exploring Valuation After a 20% Share Price Surge - Yahoo Finance

Nov 12, 2025

Nov 11, 2025

Wells Fargo Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - Nasdaq

Nov 11, 2025

BridgeBio Pharma (BBIO): Wells Fargo Raises Price Target to $84 - GuruFocus

Nov 11, 2025

Nov 10, 2025

BridgeBio Pharma CEO Kumar Neil sells $5m in shares By Investing.com - Investing.com Australia

Nov 10, 2025

BridgeBio Pharma CEO Kumar Neil sells $5m in shares - Investing.com

Nov 10, 2025

Bridgebio Pharma Insider Sold Shares Worth $4,983,111, According to a Recent SEC Filing - MarketScreener

Nov 10, 2025

Pfizer’s Advertising Challenge Against BridgeBio’s Attruby Leverages US FDA Untitled Letter - Citeline News & Insights

Nov 10, 2025

Sustained drop in all-cause mortality observed with BridgeBio’s acoramidis - The Pharma Letter

Nov 10, 2025

BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing - MarketScreener

Nov 10, 2025

Can machine learning forecast BridgeBio Pharma Inc. recoveryTrade Risk Assessment & Low Risk High Reward Ideas - newser.com

Nov 10, 2025

Nov 09, 2025

Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com

Nov 09, 2025

BridgeBio Pharma’s Global Expansion Shockwave: Why Investors Are Buzzing! - Smartkarma

Nov 09, 2025

BridgeBio (BBIO) Reports Promising Data for Acoramidis in Cardia - GuruFocus

Nov 09, 2025

BridgeBio presents data from ATTRibute-CM study on acoramidis - TipRanks

Nov 09, 2025

Nov 08, 2025

BridgeBio Pharma Reports Significant All-Cause Mortality Reductions with Acoramidis in Variant ATTR-CM Patients at AHA Scientific Sessions 2025 - Quiver Quantitative

Nov 08, 2025

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - GlobeNewswire

Nov 08, 2025

Using Bollinger Bands to evaluate BridgeBio Pharma Inc.2025 Earnings Surprises & Entry Point Strategy Guides - newser.com

Nov 08, 2025

JP Morgan Raises Price Target for BBIO, Maintains Overweight Rat - GuruFocus

Nov 08, 2025

Nov 07, 2025

BridgeBio Pharma Director Makes a Multi-Million Dollar Stock Move! - TipRanks

Nov 07, 2025

BridgeBio Pharma Director Ronald J Daniels Sells Over $3.8 Million in Company Stock - TradingView

Nov 07, 2025

Long term debt to total equity ratio of BridgeBio Pharma, Inc. – HAM:2CL - TradingView

Nov 07, 2025

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan

Nov 07, 2025

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry - The Manila Times

Nov 07, 2025

Will BridgeBio Pharma Inc. stock pay special dividendsDay Trade & Daily Profit Focused Screening - newser.com

Nov 07, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ceribell, Inc. (CBLL), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail

Nov 06, 2025

How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesWeekly Trend Recap & Reliable Price Breakout Signals - newser.com

Nov 06, 2025

Nov 05, 2025

Why retail investors favor BridgeBio Pharma Inc. stockJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com

Nov 05, 2025

Real time alert setup for BridgeBio Pharma Inc. performance2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com

Nov 05, 2025

Is BridgeBio Pharma Inc. stock a buy in volatile markets2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - fcp.pa.gov.br

Nov 05, 2025